EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

VDX-111 targets proliferative pathways in canine cancer cell lines

Kristen B Farrell iD, Sunetra Das, Steven K Nordeen, James R Lambert, Douglas H Thamm

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0303470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Kristen B Farrell und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, United States of America. Hauptthemen laut MEDLINE: Cell Proliferation, Signal Transduction, Antineoplastic Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

VDX-111 (also identified as AMPI-109) is a vitamin D derivative which has shown anticancer activity. To further assess the function of this compound against multiple cancer types, we examined the efficacy of VDX-111 against a panel of 30 well characterized canine cancer cell lines. Across a variety of cancer types, VDX-111 induced widely variable growth inhibition, cell death, and migration inhibition, at concentrations ranging from 10 nM to 1 μM. Growth inhibition sensitivity did not correlate strongly with tumor cell histotype; however, it was significantly correlated with the expression of genes in multiple cell signaling pathways, including the MAPK and PI3K-AKT pathways. We confirmed inhibition of these signaling pathways as likely participants in the effects of VDX-111. These results suggest that a subset of canine tumors may be sensitive to treatment with VDX-111, and suggests possible predictive markers of drug sensitivity and pharmacodynamic biomarkers of drug exposure that could be employed in future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell ProliferationSignal TransductionAntineoplastic AgentsDogsAnimalsCell Line, TumorNeoplasmsCell MovementPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktDog DiseasesGene Expression Regulation, NeoplasticVitamin D

Substanzen

Antineoplastic AgentsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktVitamin D

Autor:innen und Institutionen

  • Department of Clinical Sciences, Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, United States of America.
  • Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States of America.

ORCID-Profile: Kristen B Farrell

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Farrell, K. B., Das, S., Nordeen, S. K., Lambert, J. R., & Thamm, D. H. (2024). VDX-111 targets proliferative pathways in canine cancer cell lines. PLOS ONE. https://doi.org/10.1371/journal.pone.0303470

Vancouver

Farrell KB, Das S, Nordeen SK, Lambert JR, Thamm DH. VDX-111 targets proliferative pathways in canine cancer cell lines. PLOS ONE. 2024. doi:10.1371/journal.pone.0303470

BibTeX
@article{Farrell2024,
  author = {Farrell, Kristen B and Das, Sunetra and Nordeen, Steven K and Lambert, James R and Thamm, Douglas H},
  title = {VDX-111 targets proliferative pathways in canine cancer cell lines},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0303470}
}
Kostenlos starten →